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Penicillin resistance among Streptococcus pneumoniae isolates has rapidly emerged in Poland during the last
decade and has reached prevalence levels of up to 14.4% in 1997. In order to investigate the nature of this
increase, a molecular epidemiological analysis of non-penicillin-susceptible multidrug-resistant pneumococci
isolated in 1995 and 1996 was conducted. Thirty-seven patients who suffered mainly from upper respiratory
tract infections and pneumococcal pneumonia were enrolled in this study. The medical centers to which the
patients were admitted were located in 16 Polish towns across the country. Eight distinct BOX PCR types were
observed, representing 14 subtypes. Restriction fragment end labeling (RFEL) analysis divided the pneumo-
coccal strains into 16 distinct types. By combining the BOX PCR and RFEL data, four genetically distinct
clusters of strains were identified. Two clusters represented the genetic clones 23F and 9V, which have recently
emerged all over the world. The two other genetic clusters, which represented serotypes 23F and 6B, clearly
predominated in the analyzed collection of Polish non-penicillin-susceptible pneumococcal strains. Since the
latter clusters did not match any of the 133 RFEL types of non-penicillin-susceptible pneumococci collected in
15 other countries, their Polish clonal origin is most likely.
Streptococcus pneumoniae (pneumococcus) continues to be a
common cause of serious and life-threatening infections, such
as pneumonia, bacteremia, and meningitis, and of noninvasive
infections, such as otitis media and sinusitis (3). In addition,
pneumococci are often part of the normal nasopharyngeal
flora. Especially in young children, pneumococcal colonization
often occurs. Colonization is an important risk factor: children
colonized with S. pneumoniae more often develop acute otitis
media than children who are not colonized (9, 18, 33, 43).
Until the 1960s, pneumococci were considered uniformly
susceptible to penicillin, and sensitivity tests were hardly ever
performed. In 1967, the first isolation of penicillin-resistant
pneumococci was reported in Australia (12). Subsequently,
penicillin-resistant pneumococci have been isolated in Papua
New Guinea and South Africa (20, 22, 31). In the late 1970s
and 1980s, rates of resistance, including multiple resistance,
have increased in Western countries, particularly in Spain, with
resistance levels of up to 50% (11, 20, 22, 31). A recent epi-
demiological study performed in the United States has dem-
onstrated that 25% of invasive pneumococci are non-penicillin
susceptible (17). The emergence of high-level resistance to
penicillin, particularly in combination with other resistance
determinants, is a serious threat for current treatment strate-
gies.
Several investigators have reported the international spread
of multiply resistant pneumococcal clones. Soares and cowork-
ers have reported the spread of a drug-resistant clone of sero-
type 6B from Spain to Iceland in the late 1980s (37). This has
resulted in an epidemic of this clone, which was isolated with
frequencies of up to 12% in 1992 (21). In 1991, Munoz and
colleagues reported evidence for the intercontinental spread of
a multiply resistant clone of S. pneumoniae serotype 23F from
Spain to the United States (24). This clone has subsequently
disseminated through the United States (23). Finally, in 1995
Gasc and colleagues reported the spread of a multiply resistant
pneumococcal clone of serogroup 9 from Spain to France (10).
The international clones 23F and 9V have been identified in
many countries in different parts of the world (14, 28). Besides
the international spread of the clones 6B, 23F, and 9V, novel
penicillin-resistant and multiply resistant clones that tend to
spread in an epidemic manner have been observed in the
former Czechoslovakia, Spain, Japan, and South Africa (4, 30,
34, 42).
Penicillin resistance among pneumococcal isolates has rap-
idly emerged in Poland during the last decade. The percentage
of non-penicillin-susceptible strains has increased from 0 to
3% in 1990 to 1993 (1, 19) to 14.3% in 1996 (39) and 14.4% in
1997 (38). In order to identify the nature of the increase in the
prevalence of non-penicillin-susceptible pneumococci in Po-
land, a molecular epidemiological study was conducted. To this
end, strains were isolated in 1995 and 1996 from 37 patients
who suffered mainly from upper respiratory tract infections
and pneumococcal pneumonia and who were diagnosed in 19
different clinical centers located in 16 towns across the country.
The pneumococcal isolates were characterized by BOX PCR
typing, restriction fragment end labeling (RFEL) analysis, pen-
icillin-binding protein (PBP) genotyping, serotyping, and drug
susceptibility testing.
MATERIALS AND METHODS
Bacterial isolates. Non-penicillin-susceptible S. pneumoniae strains were iso-
lated from 37 Polish patients in 1995 and 1996. A single pneumococcal isolate
per patient per infection was analyzed. Bacteriological diagnosis was carried out
in 19 distinct medical centers. These centers were located in 16 Polish towns
across the country (Fig. 1). The clinical, bacteriological, and demographic pa-
rameters are listed in Table 1.
Biochemical characterization, serotyping, and susceptibility testing. The iso-
lates were determined to be S. pneumoniae by investigating their optochin sus-
* Corresponding author. Mailing address: Laboratory of Pediatrics/
Room Ee1500, Erasmus University Rotterdam, P.O. Box 1738, 3000
DR Rotterdam, The Netherlands. Phone: 31-10-4088224. Fax: 31-10-
4089486. E-mail: hermans@kgk.fgg.eur.nl.
1739
ceptibility and bile solubility (25). All pneumococci were serotyped in the Sera
and Vaccines Central Research Laboratory in Warsaw on the basis of capsular
swelling (Quellung reaction) observed microscopically after suspension in anti-
sera prepared at Statens Seruminstitut, Copenhagen, Denmark (8).
The susceptibilities of pneumococcal strains were determined in the Sera and
Vaccines Central Research Laboratory in Warsaw according to the guidelines of
the National Committee for Clinical Laboratory Standards (26) by the broth
microdilution method in cation-adjusted Mueller-Hinton II broth (Beckton
Dickinson, Oxford, United Kingdom) supplemented with 5% lysed horse blood.
The following panel of antimicrobial agents was tested: penicillin (Polfa, Poznan,
Poland), amoxicillin (SmithKline Beecham, Brentford, United Kingdom), cefo-
taxime (Roussel, Paris, France), doxycycline (Polfa), chloramphenicol (Polfa),
erythromycin (Polfa), lincomycin (Upjohn, Kalamazoo, Mich.), vancomycin (Eli
Lilly, Indianapolis, Ind.), rifampin (Polfa), ofloxacin (Hoechst-Roussel, Kansas
City, Kans.), sparfloxacin (Rhone-Poulenc, Courbevoie cedex, France), and co-
trimoxazole (trimethoprim with sulfamethoxazole) (Polfa). For doxycycline, lin-
comycin, and sparfloxacin susceptibility testing, French interpretative criteria
were applied (6). The microdilution panels were prepared by a single senior
technician. The quality control strains S. pneumoniae ATCC 49619 and Staphy-
lococcus aureus ATCC 29213 were included in each run.
RFEL analysis and BOX PCR typing. Typing of pneumococcal strains by
RFEL analysis was performed as described by Van Steenbergen et al. (41) and
adapted by Hermans et al. (16). Briefly, purified pneumococcal DNA was di-
gested with the restriction enzyme EcoRI. The DNA restriction fragments were
end labeled at 72°C with [a-32P]dATP by using DNA polymerase (Goldstar;
Eurogentec, Seraing, Belgium). The radiolabeled fragments were denatured and
separated electrophoretically on a 6% polyacrylamide sequencing gel containing
8 M urea. Subsequently, the gel was transferred onto filter paper, vacuum dried
(HBI, Saddlebrook, N.Y.), and exposed for variable lengths of time at room
temperature to ECL Hyperfilms (Amersham, Bucks, United Kingdom).
BOX PCR typing was carried out in a single laboratory as described before
(40). Briefly, 50 ng of pneumococcal DNA was amplified by PCR (4 min at 94°C
[predenaturation]; 40 cycles of 1 min at 94°C, 1 min at 60°C, and 2 min at 74°C;
and 2 min at 74°C [extension]), using primer BOX-A (59ATACTCTTCGAAA
ATCTCTTCAAAC), which was designed from the primary structure of the
BOX repeat motif. The amplified products were separated on a 1.5% agarose
gel. Gels were stained with ethidium bromide, after which the banding patterns
were evaluated visually. BOX PCR patterns showing a single band difference
were defined as nonidentical types (e.g., 1, 2, and 3). Identical banding patterns
varying in the intensity of one or more bands were defined as subtypes (e.g., 7,
7.1, and 7.2).
PBP genotyping. Genetic polymorphism of the penicillin resistance genes
pbp1a, pbp2b, and pbp2x was investigated by restriction fragment length poly-
morphism (RFLP) analysis. To this end, we amplified the genes by PCR and
analyzed the digested DNA products by agarose gel electrophoresis. PCR am-
plification of the PBP-encoding genes was performed in a 50-ml PCR buffer
system containing 75 mM Tris-HCl (pH 9.0), 20 mM (NH4)2SO4, 0.01% (wt/vol)
Tween 20, 1.5 mM MgCl2, 0.2 mM deoxynucleoside triphosphates, 10 pmol of
the individual primers, 0.5 U of DNA polymerase (Eurogentec), and 10 ng of
purified chromosomal DNA. Cycling was performed in a PTC-100 Programma-
ble Thermal Controller (MJ Research, Watertown, Mass.) and consisted of the
following steps: predenaturation at 94°C for 1 min; 30 cycles of 1 min at 94°C, 1
min at 52°C, and 2 min at 72°C; and a final extension at 72°C for 3 min. The
primers used to amplify the genes pbp1a, pbp2b, and pbp2x were described
previously (5, 7, 24).
The amplification products (5 ml) were digested with the restriction endonu-
clease HinfI and separated by electrophoresis in 2.5% agarose gels containing
0.53 Tris-borate-EDTA and 0.1 mg of ethidium bromide per ml (5 mm thick)
(Agarose MP; Boehringer Mannheim, Almere, The Netherlands). Gels were run
in 0.53 Tris-borate-EDTA containing 0.1 mg of ethidium bromide per ml at 20
mA for 4 h. Prior to electrophoresis, samples were mixed with a 53-concentrated
layer mix consisting of 50% glycerol in water and 0.8 mg of bromophenol blue
per ml. Gels were photographed with a Polaroid MP4 Landcamera and Polaroid
667 films. The different PBP genotypes are represented by a three-number code
(e.g., 6-14-43, referring to the RFLP patterns of the genes pbp1a [pattern 6],
pbp2b [pattern 14], and pbp2x [pattern 43], respectively.
Computer-assisted analysis of the DNA banding patterns. The RFEL types
were analyzed by using the Windows version of the Gelcompar software version
4 (Applied Maths, Kortrijk, Belgium) after imaging the RFEL autoradiograms
with the Image Master DTS (Pharmacia Biotech, Uppsala, Sweden). To this end,
the DNA fragments in the molecular size range of 160 to 400 bp were explored.
The DNA banding patterns were normalized by using pneumococcus-specific
bands present in the RFEL banding patterns of all strains. Comparison of the
banding patterns was performed by the unweighted pair group method with
arithmetic averages (29) and with the Jaccard similarity coefficient applied to
peaks (36). Computer-assisted analysis and the methods and algorithms used in
this study were according to the instructions of the manufacturer of Gelcompar.
A tolerance of 1.5% in band positions was applied during comparison of the
DNA patterns. Identical DNA types were arbitrarily defined as those with RFEL
homologies higher than 95%. Cluster codes I to IV refer to clusters of pneumo-
coccal strains displaying RFEL types with homologies higher than 80% that were
confirmed to be genetically related by using BOX PCR typing (identical BOX
PCR types or subtypes).
RESULTS
The molecular epidemiology of non-penicillin-susceptible
multidrug-resistant pneumococci in Poland was investigated.
Thirty-seven patients who suffered mainly from upper and
lower respiratory tract infections (n 5 20 and 13, respectively)
were enrolled in this study. In addition, three patients suffered
from otitis media, a brain abscess, and conjunctivitis, respec-
tively. The clinical diagnosis of one patient was unknown. The
medical centers to which the patients were referred were lo-
cated in 16 Polish towns across the country (Fig. 1). The clin-
ical and demographic parameters are listed in Table 1.
The 37 non-penicillin-susceptible pneumococcal strains
were characterized by RFEL analysis and BOX PCR typing.
RFEL analysis divided the 37 pneumococcal strains into 16
distinct types (Fig. 2; Table 1). Eight distinct BOX PCR types
were observed, representing 14 subtypes (Fig. 3; Table 1).
When RFEL and BOX PCR analyses were combined, four
genetically distinct clusters of strains (designated I, II, III, and
IV) were identified. Within these clusters, genetic relatedness
of the strains was demonstrated by both RFEL analysis and
BOX PCR (sub)typing. Clusters I, II, III, and IV consisted of
12, 3, 11, and 7 strains, respectively. Each cluster was repre-
sented by strains that originated from different centers (Table
1). The remaining four strains did not fulfill the cluster criteria.
Comparison of the Polish RFEL types with 133 genotypes
present in the international RFEL data library representing 15
other countries (13, 14) revealed that the genetic clusters II
and IV matched the Spanish pandemic clone 23F (RFEL type
15) and the Spanish-French international clone 9V (RFEL
FIG. 1. Map of Poland. The medical centers collaborating in this study are as
follows: 1, Mother and Child Institute, Warsaw; 2, Health Care Center Praga-
Polnoc, Warsaw; 3, Nieklanska Street Hospital, Warsaw; 4, Sienna Street Hos-
pital, Warsaw; 5, Health Care Center, Kolobrzeg; 6, Regional Hospital, Gdansk;
7, Health Care Center, Tczew; 8, Health Care Center, Braniewo; 9, Regional
Children’s Hospital Olsztyn; 10, Regional Hospital, Suwalki; 11, Medical Uni-
versity, Bydgoszcz; 12, Health Care Center, Gorzow Wielkopolski; 13, Health
Care Center, Czestochowa; 14, Health Care Center, Kedzierzyn Kozle; 15, Jan
Bober Center for Microbiology and Autovaccines, Krakow; 16, Health Care
Center, Myslenice; 17, Health Care Center, Mielec; 18, Health Care Center,
Sanok; and 19, Regional Hospital, Lomza.
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type 23), respectively (data not shown). The remaining 14
Polish RFEL types did not match any of the 133 non-Polish
types present in the international library.
The 37 non-penicillin-susceptible pneumococci from Poland
represented seven distinct serotypes (Table 1). The most pre-
dominant serotypes were 23F (n 5 15), 6B (n 5 12), and 9V
(n 5 6). Serotypes 6A, 14, and 19A were all observed once in
the Polish collection. Strain 31 displayed a rough phenotype
and could not be serotyped. Serotypes 23F, 6B, and 9V in-
cluded 6, 5, and 2 RFEL types, respectively, whereas the re-
maining three serotypes (6A, 14, and 19A) were restricted to
single RFEL types. The clusters I, II (pandemic clone 23F),
and III displayed the serotypes 23F, 23F, and 6B, respectively.
Genetic cluster IV (pandemic clone 9V) harbored both sero-
types 9V (n 5 6) and 14 (n 5 1), indicating horizontal transfer
of capsular genes within this cluster.
The penicillin MICs of the pneumococcal strains varied
from 0.12 to 8.0 mg/ml. Within the genetic clusters, various
resistance profiles were observed, ranging from lack of suscep-
tibility to penicillin and doxycycline only to multidrug resis-
tance against penicillins, cefotaxime, co-trimoxazole, doxycy-
cline, chloramphenicol, erythromycin, and lincomycin. Genetic
cluster I had the highest penicillin MICs (up to 8 mg/ml), as
well as the greatest multidrug resistance (Table 1). The lowest
penicillin MICs were observed for isolates of genetic cluster
III. The resistance patterns of these strains demonstrated their
relative susceptibilities to the antimicrobial agents tested. Nev-
ertheless, all members of cluster III were multidrug resistant,
TABLE 1. Microbiological parameters of 37 penicillin-resistant pneumococcal isolates and clinical and demographic data for the patients
Patient Pneumococcal strain
Age (yr) Sex Clinicaldiagnosisa Center
b Strain
no.
Clinical
originc
Penicillin
MIC (mg/ml)
Resistance
profiled Serotype
BOX PCR
type
RFEL typee
(cluster)f
PBP
genotype
,1 Female URTI 7 39 Nose 4.0 PAXCDELT 23F 1 106 (I) 6-2-53
,1 Male URTI 7 40 Nose 4.0 PAXCDELT 23F 1 106 (I) 6-1-53
Child —g URTI 6 32 Nose 4.0 PAXCDELT 23F 1 106 (I) 6-1-53
1 Male URTI 7 26 Nose 4.0 PAXCDELT 23F 1 105 (I) 6-18-53
Child Male URTI 17 29 Nose 4.0 PAXCDELT 23F 1 105 (I) 6-18-56
1 Male LRTI 1 6 Throat 8.0 PAXCDET 23F 1 105 (I) 16-3-1
,1 Male LRTI 7 9 Blood 4.0 PAXCDELT 23F 1 105 (I) 6-18-53
1 Male URTI 14 22 Nose 2.0 PAXCDELT 23F 1 145 (I) 6-14-43
6 Male Otitis media 4 151 Ear 4.0 PA*CDE** 23F 1 44 (I) 6-14-43
4 Female URTI 3 178 Nose 8.0 PA*CDE** 23F 1 44 (I) 6-14-1
4 Male URTI 4 233 Throat 8.0 PA*CDE** 23F 1 45 (I) 6-14-1
5 Female URTI 4 234 Throat 8.0 PA*CDE** 23F 1 45 (I) 6-14-1
Adult Female LRTI 2 4 Sputum 2.0 PAXCDET 23F 2 15 (II) 1-1-1
13 Female LRTI 18 16 BAL 2.0 PAXDET 23F 2.1 15 (II) 1-1-1
3 Male URTI 16 33 Throat 2.0 PAXCDET 23F 2 15 (II) 1-18-1
57 Male Brain abscess 12 8 CSF 0.5 PCDELT 19A 3 104 7-17-52
55 Male LRTI 10 2 BAL 1.0 PCT 6A 4 97 2-5-51
— — — 8 31 — 1.0 PD Rough 5 148 0h-2-54
3 Female URTI 7 36 Nose 1.0 PCDELT 6B 6 147 0-1-54
14 Male LRTI 9 12 Sputum 0.12 PCDELT 6B 7 98 (III) 2-2-9
7 Male LRTI 9 13 Sputum 0.12 PCDELT 6B 7 98 (III) 2-2-9
3 Female LRTI 9 14 Blood 0.12 PCDELT 6B 7.1 98 (III) 2-2-9
1 Male URTI 13 35 Nose 0.12 PCDELT 6B 7.2 98 (III) 2-18-9
6 Male URTI 16 34 Nose 0.12 PCDELT 6B 7.1 98 (III) 2-18-9
Adult — LRTI 11 17 Sputum 0.12 PCDELT 6B 7.3 102 (III) 2-2-9
2 Male URTI 14 23 Nose 0.12 PDE 6B 7.3 102 (III) 2-2-9
Child Male Conjunctivitis 2 30 Eye 0.12 PDEL 6B 7.1 102 (III) 2-2-9
12 Male LRTI 9 15 Blood 0.12 PDEL 6B 7.2 101 (III) 2-2-9
,1 — LRTI 2 5 Throat 0.12 PDEL 6B 7.3 99 (III) 2-2-9
5 Male URTI 17 27 Nose 0.12 PCDET 6B 7.4 99 (III) 2-2-9
Child Female URTI 7 24 Nose 1.0 PACDT 9V 8 23 (IV) 1-1-1
Adult Male URTI 17 38 Nose 1.0 PAXCDET 9V 8.1 23 (IV) 1-2-1
Adult Female LRTI 6 1 Pleural
fluid
1.0 PAXCDET 9V 8.1 23 (IV) 1-1-1
Child Male URTI 5 10 Nose 1.0 PAXCDET 9V 8 23 (IV) 1-5-1
Adult — LRTI 15 11 Sputum 2.0 PAXCDELT 14 8 23 (IV) 1-5-1
Child Female URTI 3 37 Throat 0.5 PXCDT 9V 8.1 23 (IV) 1-2-1
10 Female URTI 19 181 Throat 1.0 PA*C** 9V 8.1 140 (IV) 1-1-1
a URTI, upper respiratory tract infection; LRTI, lower respiratory tract infection.
b See Fig. 1.
c BAL, broncheoalveolar lavage; CSF, cerebrospinal fluid.
d P, penicillin G; A, amoxicillin; X, cefotaxime, C, chloramphenicol; D, doxycycline; E, erythromycin; L, lincomycin; T, trimethoprim-sulfamethoxazole (co-
trimoxazole); p, susceptibility to cefotaxime, lincomycin, and co-trimoxazole was not tested.
e The arbitrary cutoff value for an identical RFEL type is 95%; RFEL codes refer exclusively to the genetic distances calculated by using the entire collection of 147
pneumococcal RFEL types, in which the Polish genotypes were included (see Materials and Methods) (13, 14).
f See Fig. 2.
g —, data not available.
h Unknown PBP genotype.
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i.e., resistant to three or more antibiotics. None of the isolates
were resistant to vancomycin, rifampin, and fluoroquinolones.
The penicillin resistance profiles of the pneumococcal
strains were investigated in further detail by PBP genotyping.
To this end, the penicillin resistance genes pbp1a, pbp2b, and
pbp2x were subjected to RFLP analysis (Fig. 4). The genetic
clusters II (pandemic clone 23F) and IV (pandemic clone 9V)
included two and three distinct PBP genotypes, respectively
(Table 1). The polymorphism was restricted to pbp2b. Similar
results were observed for cluster III: there were two distinct
PBP genotypes that differed only in the pbp2b gene. For cluster
I, seven distinct PBP genotypes were observed; in contrast to
the case for the other three genetic clusters, genetic polymor-
phism was demonstrated in pbp1a (two types), pbp2b (five
types), and pbp2x (four types). Except for clusters II and IV,
representing pandemic clones 23F and 9V, respectively, no
overlap was observed between the PBP genotypes of the four
clusters. Similarly, the four genotypes that were observed only
once in the Polish collection also displayed unique PBP geno-
types. The polymorphism of the PBP-encoding genes within
clusters II and IV was remarkable, as the majority of the
pandemic 23F and 9V isolates that are now present in the
international data library (51 23F strains from 10 countries
[96%] and 31 9V strains from 5 countries [97%]) display PBP
genotype 1-1-1 (13, 14).
Comparison of the PBP genotypes of the individual genes
pbp1a, pbp2b, and pbp2x between the Polish non-penicillin-
susceptible strains and 185 Dutch penicillin-susceptible pneu-
mococcal meningitis isolates (15, 32) revealed the exclusive
presence of penicillin-susceptible pbp1a and pbp2b genotypes
among the Polish clusters I, III, and IV. Two strains of cluster
IV (pandemic clone 9V; strains 37 and 38 with penicillin MICs
of 0.5 and 1.0 mg/ml, respectively) displayed the predominant
penicillin-susceptible pbp2b genotype 2 (Fig. 4; Table 1). In
addition, the majority of the strains belonging to cluster III
displayed the predominant penicillin-susceptible pbp1a-pbp2b
genotype 2-2 (penicillin MIC of 0.12 mg/ml). Finally, the ma-
jority of cluster I displayed the penicillin-susceptible pbp1a
genotype 6 (penicillin MICs ranging from 2.0 to 8.0 mg/ml);
this genotype was observed only once in the collection of 185
Dutch penicillin-susceptible pneumococci.
Among the pbp1a, pbp2b, and pbp2x genotypes that are
FIG. 2. Genetic relatedness of 37 Polish non-penicillin-susceptible pneumococcal strains based on the RFEL banding patterns of the isolates. The RFEL
fingerprints, their relatedness (dendrogram), strain numbers, and genetic cluster codes (Roman numerals) are depicted. Cluster codes I to IV refer to clusters of
pneumococcal strains displaying RFEL types with homologies higher than 80% that are confirmed to be genetically related by BOX PCR typing (identical BOX PCR
types or subtypes).
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restricted to non-penicillin-susceptible pneumococci (13, 14),
the presence of pbp1a genotype 1 was observed among clusters
II (clone 23F) and IV (clone 9V) (Table 1). In addition, the
pbp2b genotypes 1 and 18 and the pbp2x genotype 1 were
observed in three genetic clusters. These data indicate hori-
zontal exchange of penicillin resistance genes between pneu-
mococcal strains of the different Polish clusters.
DISCUSSION
Penicillin resistance among pneumococcal isolates has rap-
idly emerged in Poland during the last decade. The percentage
of non-penicillin-susceptible strains has increased from 0 to
3% in 1990 to 1993 (1, 19) to 14.3% in 1996 (39) and 14.4% in
1997 (38). In order to identify the nature of the increase in the
prevalence of non-penicillin-susceptible pneumococci in Po-
land, a molecular epidemiological study was conducted. The
emergence of four genetically distinct non-penicillin-suscepti-
ble multidrug-resistant pneumococcal clusters was clearly dem-
onstrated. Clusters II and IV represented the genetic clones
23F (24) and 9V (11), respectively, which have recently
emerged all over the world (13, 14). In addition, the two other
clusters, I and III, predominated in the collection of non-
penicillin-susceptible pneumococci from Poland. Since these
clusters did not match any of the 133 RFEL types of non-
penicillin-susceptible pneumococci collected in 15 other coun-
tries and present in the international data library of RFEL
types (13, 14), their Polish origin is most likely.
Various researchers have reported horizontal transfer of
capsular genes (2, 13–15). The high frequency of capsular
transfer may have consequences for the outcome of current
vaccine strategies, which focus on the use of a restricted num-
ber of distinct capsular polysaccharides. The use of multivalent
conjugate vaccines may shift the capsular distribution towards
capsular types that are not present in these vaccines. Such a
shift might be enhanced by the frequent horizontal exchange of
capsular genes. Genetic cluster IV (pandemic clone 9V) har-
bored both serotypes 9V (n 5 6) and 14 (n 5 1). These
serotypes are known to occur in this international clone (13,
14). The Polish strains that were genetically related to the
pandemic clone 23F (cluster II), which harbors serotypes 23F,
19F, 14, 9N, 19A, and 3 (13, 14, 27), displayed only the ances-
tral serotype 23F.
Within the four genetic clusters, RFLP of the PBP-encoding
genes was often observed, in particular in pbp2b. This finding
FIG. 3. DNA fingerprint patterns of the 14 distinct BOX PCR (sub)types represented by the 37 Polish non-penicillin-susceptible pneumococcal strains. Lane
numbers indicate BOX PCR type codes. Numbers at the left indicate the sizes of standard DNA fragments in base pairs.
FIG. 4. DNA fingerprint patterns of the pbp1a (n 5 5), pbp2b (n 5 7), and pbp2x (n 5 8) genotypes represented by the 37 Polish non-penicillin-susceptible
pneumococcal strains. Lane numbers indicate PBP genotype codes. Numbers at the left indicate the sizes of standard DNA fragments in base pairs.
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indicates frequent horizontal transfer of the penicillin resis-
tance genes. PBP genotype 1-1-1 was observed in clusters II
(pandemic clone 23F) and IV (pandemic clone 9V). In a recent
study by Hermans and coworkers (13), the vast majority of
isolates of the pandemic clones 23F and 9V also displayed the
PBP genotype 1-1-1. In that study, PBP genotype 1-1-1 was
displayed by 41% of the strains collected in 15 other countries
and represented 20 of the 133 distinct RFEL types. In addition,
genetic polymorphism in the penicillin resistance genes of the
pandemic clones 9V and 23F was rarely observed. However, in
5 of the 10 Polish strains that were related to the pandemic
clones 9V and 23F, differences in the PBP genotypes were
observed, suggesting that in Poland horizontal transfer of pen-
icillin resistance genes, in particular pbp2b, occurs more fre-
quently in these clones than in those present in the other
countries. The pbp2b genotypes 18 (observed only in Poland so
far) and 1 and the pbp2x genotype 1 were observed in three of
the four genetic clusters. These data suggest that these PBP
genotypes have spread in the Polish population of non-peni-
cillin-susceptible pneumococci by horizontal gene transfer.
The strains belonging to cluster III invariably displayed low
penicillin MICs of 0.12 mg/ml. In addition, the majority of
these strains displayed the penicillin-susceptible pbp1a-pbp2b
genotype 2-2. Although the predictive value of PBP genotyping
for pneumococcal penicillin resistance can be debated for
methodological reasons, this observation is in concordance
with data from Smith and coworkers (35), who have demon-
strated that in pneumococci with low penicillin MICs, pbp2b is
usually not affected by mutations.
In summary, penicillin resistance has rapidly emerged in
Poland over the last decade. Although the pandemic clones 9V
and 23F are present in this country, the nationwide emergence
of two novel multidrug-resistant pneumococcal clones that are
presumably of Polish origin has clearly contributed to the in-
crease in the prevalence of non-penicillin-susceptible pneumo-
cocci in Poland.
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